Professor CHAN Ho Yin Edwin


(Office): Rm 509B, Mong Man Wai Building
(Lab): Rm 509A, Mong Man Wai Building

People CHY3


(Office): (852) 3943 4021
(Lab): (852) 3943 8032

Fax (852) 2603 7732
Email This email address is being protected from spambots. You need JavaScript enabled to view it.



1999 Ph.D. University of Cambridge
1995 B.Sc. The Chinese University of Hong Kong


  • Professor, School of Life Sciences
  • Director, Biochemistry Programme
  • Deputy Director, Natural Sciences Programme, Science Faculty
  • Director, Laboratory of Drosophila Research
  • Warden, Postgraduate Halls

Research Interests

  • Human disease modelling
  • Cellular, genetic and biochemical analyses of RNA and protein toxicity in neurological diseases
  • Therapeutic intervention of neurological diseases

Representative Publications

  • Chen, Z.S., Ou, M., Taylor, S., Dafinca, R., Peng, S.I., Talbot, K.* and Chan, H.Y.E.* (2023) Mutant GGGGCC RNA prevents YY1 from binding to Fuzzy promoter which stimulate Wnt/b-catenin pathway in C9ALS/FTD. Nat. Commun. 14(1):8420
  • An, Y., Chen, Z.S., Chan, H.Y.E.* and Ngo, J.C.K.* (2022) Molecular insights into the interaction of CAG trinucleotide RNA repeats with nucleolin and its implication in polyglutamine diseases. Nucl. Acids Res. 50(13), 7655-7668.
  • Peng, S.I., Leong, L.I., Sun, J.K., Chen, Z.S., Chow, H.M. and Chan, H.Y.E.* (2022) A peptide inhibitor that rescues polyglutamine-induced synaptic defects and cell death through suppressing RNA and protein toxicities. Mol. Ther. Nucleic Acids 29, 102-115.
  • Peng, S., Guo, P., Lin, X., An, Y., Sze, K.H., Lau, M.H.Y., Chen, Z.S., Wang, Q., Li, W., Sun, J.K., Ma, S.Y., Chan, T.F., Lau, K.F., Ngo, J.C.K., Kwan, K.M., Wong, C.H., Lam, S.L., Zimmerman, S.C., Tuccinardi, T., Zuo, Z., Au Yeung, H.Y., Chow, H.M. and Chan, H.Y.E.* (2021) CAG RNAs induce DNA damage and apoptosis by silencing NUDT16 expression in polyglutamine degeneration. Proc. Natl. Acad. Sci. USA. 118(19) e2022940118
  • Chen, Z.S., Huang, X., Talbot, K. and Chan, H.Y.E.* (2021) A fine balance between Prpf19 and Exoc7 in achieving degradation of aggregated protein and suppression of cell death in spinocerebellar ataxia type 3. Cell Death Dis. 12(2):136
  • Zhang, Q., An, Y., Chen, Z.S., Koon, A.C., Lau, K.F., Ngo, J.C.* and Chan, H.Y.E.* (2019) A peptidylic inhibitor for neutralizing r(GGGGCC)exp-associated neurodegeneration in C9ORF72-associated amyotrophic lateral sclerosis and frontotemporal dementia. Mol. Ther. Nucleic Acids 16, 172-185.
  • Chen, Z.S., Li, L., Peng, S., Chen, F.M., Zhang, Q., An, Y., Lin, X., Li, W., Chan, T.F., Lau, K.F., Ngo, J.C., Wong, W.T., Kwan, K.M. and Chan, H.Y.E.* (2018) Planar cell polarity gene Fuz triggers apoptosis in neurodegenerative diseases. EMBO Rep. 19, e45419
  • Tsoi, H., Yu, A.C., Chen, Z.S., Ng, N.K., Chan, A.Y., Yuen, L.Y., Abrigo, J.M., Tsang, S.Y., Tsui, S.K., Tong, T.M., Lo, I.F., Lam, S.T., Mok, V.C, Wong, L.K., Ngo, C.K., Lau, K.F., Chan, T.F.* and Chan, H.Y.E.* (2014) A novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia. J. Med. Genet. 51, 590-595.
  • Lu, J.H., Tan, J.Q., Durairajan, S.S., Liu, L.F., Zhang, Z.H., Ma, L., Shen, H.M., Chan, H.Y.E.* and Li, M.* (2012) Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy 8, 98-108.
  • Tsoi, H., Lau, C.K., Tsang, S.Y., Lau, K.F. and Chan, H.Y.E.* (2012) CAG expansion induces nucleolar stress in polyglutamine diseases. Proc. Natl. Acad. Sci. USA. 109, 13428-13433. F1000-r1

Research Grants

  • 2024-2026, Research Grants Council (RGC) GRF Grant, Investigating the heterozygous mutational effect of the CCDC88C gene on causing spinocerebellar ataxia, $1,592,000
  • 2021-2022, Research Grants Council (RGC) GRF Grant, The role of adhesion molecule FasII/NCAM in synaptic dysfunction and neurodegeneration in myotonic dystrophy type I, $892,655
  • 2020-2022, Research Grants Council (RGC) GRF Grant, How can we handle DNA damage induced by toxic RNAs?, $1,097,419
  • 2019-2020, Research Grants Council (RGC) GRF Grant, Investigating the role of PAPD5 and its target microRNAs in RNA toxicity of polyglutamine diseases., $677,160
  • 2016-2017, Research Grants Council (RGC) GRF Grant, Dissecting the regulatory mechanism of ubiquitin E3 ligase activity and understanding the importance of such regulation in polyglutamine pathogenesis., $768,202
  • 2015-2019, The French National Research Agency (ANR)/Research Grants Council (RGC) Joint Research Scheme, Refining the bioactivity of P42, a hit therapeutic peptide, and developing a combined therapeutic peptide approach for treating Huntington’s Disease., $2,540,083
  • 2015-2017, Research Grants Council (RGC) GRF Grant, Characterization of a novel pathogenic pathway of Huntington's Disease., $877,717
  • 2014-2017, Research Grants Council (RGC) CRF Grant, Targeting RNA and protein toxicities of polyglutamine diseases using peptidylic inhibitors., $7,044,220
  • 2014-2016, Research Grants Council (RGC) GRF Grant, Characterization of a novel type of protein nuclear export signal in polyalanine expansion disease proteins., $866,032
  • 2013-2015, Health and Medical Research Fund (HMRF) Grant, An inhibitory peptide approach to simultaneously target RNA and protein toxicities in polyglutamine degeneration., $999,908
  • 2013-2015, Research Grants Council (RGC) GRF Grant, The role of nucleolin in CAG trinucleotide repeat-mediated RNA toxicity., $790,000
  • 2009-2012, Research Grants Council (RGC) GRF Grant, Probing the nuclear transport role of the mutant polyglutamine domain in neurodegeneration., $929,247
  • 2009-2011, Research Fund for the Control of Infectious Diseases Research (RFCID) Grant, Investigating the involvement of P13K/PDK-1/Akt pathways and Notch signals in SARS-CoV Membrane-induced apoptosis., $741,448
  • 2009-2010, Cure Huntington’s Disease Initiative Foundation Early Discovery Initiative Fund, USA, Using the 3B5H10 Monoclonal Antibody to Investigate Huntingtin Oligomer and Toxicity in vivo., $444,149
  • 2004-2007, Research Grants Council (RGC) Earmarked Grant, Nucleocytoplasmic transport and polyglutamine toxicity: A cellular genetic study., $1,265,677
  • 2004-2006, Research Fund for the Control of Infectious Diseases Research (RFCID) Grant, Molecular and Genetic Characterization of the SARS Coronavirus Auxiliary Protein X1 in Drosophila., $675,144
  • 2003-2007, Research Grants Council (RGC) Earmarked Grant, Genetic and proteomic studies of chaperone-mediated suppression of polyglutamine toxicity in Drosophila., $1,203,000


  • Chan, H. Y. E.; Ngo, J. C.; Wong, C.; Zhang, Q.; Peng, S. Small molecule inhibitors targeting CAG-repeat RNA toxicity in polyglutamine diseases. U.S. Patent US 10,143,666, Dec 4, 2018
  • Chan, H.Y.E.; Ngo, J.C.; Zhang, Q. Peptidylic inhibitors targeting C9ORF72 hexanucleotide repeat-mediated neurodegeneration. U.S. Patent US-2018-0214515-A1, August 2, 2018
  • Chan, H.Y.E.; Ngo, J.C.; Zhang, Q. Peptidylic inhibitor targeting CAG-repeat RNA toxicity in polyglutamine diseases. U.S. Patent US-2017-0233442-A1, August 17, 2017
  • Chan, H.Y.E.; Jensen, K.J.; Ngo, J.C.; Sorensen, K.K.; Zhang, Q.; Zuo, Z. P3 Peptidylic inhibitors for treating CAG-repeat RNA toxicity in polyglutamine diseases. U.S. Patent 62/465,513, March 10, 2017
  • Chan, H. Y. E.; Tsoi, H.; Ngo, J. C.; Lau, K. F. Therapeutic approach for polyglutamine degeneration. U.S. Patent US 9,297,798, March 29, 2016


  • 2014 Churchill College Visiting By-Fellowship, University of Cambridge, UK
  • 2011 Genetics Society of China Thirteenth Ju-Chi Li Animal Genetics Prize (第十三届李汝祺动物遗传学奖)
  • The 2009 Young Researcher Award, The Chinese University of Hong Kong
  • The 2009 Faculty Exemplary Teaching Award, Faculty of Science, The Chinese University of Hong Kong

Professional Activities

  • Member, Public Education and Communication Committee, Society for Neuroscience, USA
  • Council Member, Genetics Society of China
  • Member, Biology and Medicine Panel (Joint Research Scheme), Research Grants Council (RGC) of Hong Kong
  • Member, Ataxia Global Initiative, a worldwide multi-stakeholder research platform to systematically enhance trial-readiness in degenerative ataxias
  • Associate Editor, Frontiers in Neurodegeneration
  • Founding member, The Hong Kong Young Academy of Sciences
  • Topic Editor, Frontiers in Cellular Neuroscience
  • Editoral Board, Advances in Alzheimer's Disease
  • Editoral Board, RNA & DISEASE
  • Member, Scientific Advisory Committee, Society for Research on the Cerebellum


  • Session Chair (Models and Mechanism 1), Pan-Asian Consortium for Treatment and Research in ALS (PACTALS), Malaysia, 2023
  • Co-Founder, Rare Power Limited
  • Member, Charter of the Ataxia Global Initiative working group, Ataxia Global Initiative
  • Member, Medical Advisory Board, Advancing CTNNB1 Cures and Treatments Inc.
  • Member, Academic Committee of Asia Pacific Drosophila Neuroscience Conference, Academia Sinica, Taiwan, 2019
  • Organizer, Inaugural Asia-Pacific Drosophila Neurobiology Conference, Wuhan, China, 2017
  • Session Chair (Drosophila models for human diseases), 2nd Asia-Pacific Drosophila Research Conference, Seoul, Korea, 2013
  • Chairperson, Scientific and Medical Advisory Committee, Hong Kong Spinocerebellar Ataxia Association, 2012 – present


Current Academic/Research Positions of Lab Alumni

  • Dr. An Ying, Research Assistant Professor, School of Life Sciences, Southern University of Science and Technology, China
  • Dr. Chan Kam Leung, Lecturer, School of Chinese Medicine, CUHK
  • Dr. Chan Priscilla, Director of Research & Development (Healthcare), Nano and Advanced Materials Institute Limited, HK
  • Dr. Chen Stephen, Postdoc Fellow, University of Oxford, UK
  • Dr. Cheng Tat Cheung, CryoEM scientist, University of Gottingen, Germany
  • Dr. Chuck Chi Pang, Research Scientist, Polytide Technology Inc., Canada
  • Dr. Choi Ching Gee, Postdoc Fellow, HKU
  • Professor Choi Jonathan, Associate Professor, Department of Biomedical Engineering, CUHK
  • Dr. Huen Macy, Manager, Technology Transfer and Commercialization, Intellectual Property Management, Hong Kong Polytechnic University
  • Dr. Koon Alex Chun, Senior Lecturer, School of Life Sciences, CUHK
  • Dr. Law Carman, Postdoc Fellow, City University of Hong Kong
  • Dr. Li Li, Postdoc Fellow, College of Physics Science and Technology, Shenzhen University
  • Dr. Ng Nelson, Postdoc Fellow, HKU
  • Dr. Peng Isaac, Project Scientist, UC Irvine, USA
  • Dr. Tsoi Ho Frankie, Research Assistant Professor, Department of Pathology, HKU
  • Professor Wong Siu Lun Alan, Associate Professor, School of Biomedical Sciences, HKU
  • Dr. Wu Chi Chung, Junior Group Leader, European Center for Angioscience, Medical Faculty Mannheim, Heidelberg University
  • Dr. Zhang Qian, Clinical Trial Manager, Medpace, Bavaria, Germany